BK9042 Medical Distribution
- 1318.780
- 0.0000.00%
Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will It Be a Boost For Pharma Stocks Too?
In September, Biden unveiled a $240 million investment to combat cancer, augmenting the administration's "Cancer Moonshot", an initiative with an array of new health resources. The funding, allocated
Aclaris Therapeutics Announces Exclusive Patent License Agreement With Sun Pharma For Rights Of Deuruxolitinib; Agreement Includes Upfront Payment Of $15M Plus Milestones And Royalties
Aclaris Therapeutics Announces Exclusive Patent License Agreement With Sun Pharma For Rights Of Deuruxolitinib; Agreement Includes Upfront Payment Of $15M Plus Milestones And Royalties
Analyst Expectations for Marinus Pharma's Future
Over the past 3 months, 5 analysts have published their opinion on Marinus Pharma (NASDAQ:MRNS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a
BridgeBio Pharma Submits NDA For Acoramidis To FDA For Treatment Of Transthyretin Amyloid Cardiomyopathy
BridgeBio Pharma Submits NDA For Acoramidis To FDA For Treatment Of Transthyretin Amyloid Cardiomyopathy
Marinus Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/05/2023 260% HC Wainwright & Co. → $27 Reiterates Buy → Buy 11/08/2023 233.33% Truist Securities $32 →
Fennec Pharma Announces Incremental $5M Investment From Petrichor, Original Deal Provided Access to up to $20M of Additional Financing
Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company focused on improving the lives of children with cancer, today announced the third closing of $5
Vanda Pharma Stock Rises After FDA Accepts Gastroparesis Drug for Review
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during
What 4 Analyst Ratings Have To Say About Arrowhead Pharma
Analysts have provided the following ratings for Arrowhead Pharma (NASDAQ:ARWR) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings11200Last 30D100001M Ago0
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC: SDZNY) (OTC: SDZXF), and Aurobindo Pharma, are resisting a b
J&J CFO, Pharma Head Reportedly in Running to Be Next CEO
Theseus Pharma Terminates CEO and Medical Chief
EyePoint Pharma Surges as Wet AMD Therapy Succeeds in Mid-stage Trial
B of A Securities Initiates Coverage On Arrowhead Pharma With Buy Rating, Announces Price Target of $29
B of A Securities analyst Jason Gerberry initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $29.
Purdue Pharma Bankruptcy Settlement Heads to Supreme Court Review
HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:COCP) with a Buy and maintains $12 price target.
Cocrystal Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/04/2023 531.58% HC Wainwright & Co. → $12 Reiterates Buy → Buy 10/04/2023 531.58% HC Wainwright & Co. →
Supreme Court Decision Looms Over Purdue Pharma's $6B Opioid Settlement And Sackler Family Immunity
The fate of a $6 billion bankruptcy settlement involving Purdue Pharma, the maker of the powerful and addictive pain medication OxyContin, hangs in the balance as the U.S. Supreme Court prepares to he
Amneal Pharma in Pact With Strides to Launch Generic Vascepa
The Most Crowded Pharma Longs and Shorts, According to UBS